Mood Disorders News

About 30% of adults in the United States experienced loneliness at least once a week, and 10% reported feeling lonely every day, according to January’s Healthy Minds Monthly Poll from the American Psychiatric Association.

Poor sleep quality and low energy on the previous day were associated with incident morning headache, while higher than average energy levels and stress were linked to later-day headache onset, researchers reported in Neurology.

A biopharma company has received approval from the European Medicines Agency to commence a phase 1 clinical trial of its selective endocannabinoid reuptake inhibitor, which aims to restore healthy brain physiology.

Patients with pulmonary fibrosis who used a smartphone app that offers cognitive behavioral therapy showed improvements in anxiety levels and quality of life, according to a press release.

Jazz Pharmaceuticals’ experimental PTSD treatment failed to meet the primary endpoint in a phase 2 trial, the company announced in a press release.

Focusing on mental health is one of the most popular New Year’s resolutions U.S. adults are making for 2024, according to a press release from the American Psychiatric Association.

Repeated withdrawal from contraceptive steroids during monthly pill pause was linked to adverse mental health symptoms, according to study findings published in JAMA Network Open.

AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.

ORLANDO — Self-managing programs to address comorbidities in patients with epilepsy require more education and independence from the creators, according to a poster.

Long-term treatment with psychedelics holds the potential to transform the health care industry through millions in savings, according to an expert at a congressional briefing hosted by Johns Hopkins University.